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as 100 mg DHA/day and 140 mg ARA/day  [10] . These 
conclusions were supported by recent recommendations 
of a global expert group, based on a systematic review of 
the available scientific evidence  [11] . In contrast, an EFSA 
opinion on the compositional requirements of infant and 
follow-on formula advised that all infant and follow-on 
formula should contain relatively high amounts of 20–50 
mg DHA/100 kcal, but without the need to provide any 
ARA  [12] . At an assumed mean formula fat content of 
5.2 g 100 kcal, this recommendation would lead to a DHA 
content of 0.38–0.96% of fatty acids, higher than about 
0.2–0.3% DHA found in most DHA enriched formulae 
for term infants marketed in Europe today, which how-
ever all contain also preformed ARA at levels equal to or 
higher than the DHA content. 
 While infant formula providing both DHA and ARA 
have been evaluated in numerous controlled trials in in-
fants, the use of term infant formula with up to 1% DHA 
and no ARA is a novel approach that has not been sys-
tematically tested for its effects, suitability and safety. 
ARA is an essential component of all cell membranes. The 
amount of ARA incorporated into the developing brain 
during infancy exceeds the deposition of DHA  [1, 2] . Al-
though humans can synthesize ARA to some extent from 
linoleic acid, infants-fed formula without pre-formed 
 The long-chain polyunsaturated fatty acids (LC- 
PUFA), docosahexaenonic acid (22: 6n-3, DHA) and ara-
chidonic acid (20: 4n-6, ARA) are deposited in relatively 
large amounts in human tissues, including the brain, dur-
ing pregnancy and infancy  [1, 2] . Fetal accretion of both 
DHA and ARA during pregnancy is facilitated by their 
preferential materno-fetal transfer across the placenta 
 [3] . After birth, human milk provides both DHA and 
ARA to breastfed infants  [4] . A survey of 65 studies on the 
composition of human milk from 2,474 women world-
wide indicated a mean DHA content of 0.32% (wt/wt; 
range 0.06–1.4%), while the mean content of ARA was 
higher with 0.47% (0.24–1.0%)  [5] . For more than two 
decades, DHA along with ARA has been added to infant 
formulae in an attempt to partly mimic the nutrient sup-
ply and functional effects achieved with breast feeding 
 [6,  7] . Current compositional requirements for infant 
 formula in the European Union  [8] and globally  [9] stip-
ulate the optional addition of DHA to infant formula, 
provided that the ARA content is equal to or higher than 
the DHA content  [4, 5] , thus following the model of typ-
ical human milk composition. 
 Recently, the European Food Safety Authority (EFSA) 
determined adequate nutrient intakes of LC-PUFA for 
the majority of infants from birth to the age of 6 months 
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ARA tend to develop lower ARA levels in blood plasma 
and erythrocytes than breast-fed infants who receive both 
DHA and ARA  [13, 14] . 
 The provision of high amounts of n-3 LC-PUFA with-
out a concomitant supply of ARA has been associated 
with adverse effects on growth in premature infants  [15, 
16] . Further concerns regarding the effects of a high sup-
ply of DHA without increasing ARA intakes to infants are 
raised by the findings of a randomised controlled trial as-
signing term infants to formula providing either no LC-
PUFA, or different levels of DHA intakes of 0.32, 0.64 and 
0.96% at the same ARA level of 0.64%, with developmen-
tal testing of the participating children up to the age 6 
 [17] . While positive effects in tests on word production, 
a card sorting task and an intelligence test were observed 
with the two lower DHA doses, performance of children 
assigned to the highest DHA dose of 0.96% but with a re-
duced ratio of dietary ARA to DHA was attenuated  [17] . 
Nonhuman primates were fed these same DHA and ARA 
intakes, and various regions of their brains were anal-
ysed. The formula with 0.96% DHA significantly reduced 
ARA in all regions of the brain analysed despite the fact 
that the higher DHA intake was accompanied by 0.64% 
ARA  [18] . These human and nonhuman primate results 
question the suitability and safety of the approach recom-
mended by EFSA, that is, to provide infant formula from 
birth with up to 1% of fatty acids as DHA without a pro-
portional increase in the intake of ARA. 
 It is widely agreed that any major change in infant for-
mula composition should be subjected to a full pre-clin-
ical and clinical evaluation of nutritional adequacy and 
safety prior to its introduction into the market  [19, 20] . 
We consider it premature to accept the use of formula for 
infants from birth with the addition of 20–50 mg/100 
kcal DHA to infant formula without added ARA in the 
absence of confirmed data on the suitability and safety 
from a thorough clinical evaluation of this novel ap-
proach. 
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